Histological diagnostic discrepancy and its clinical impact in bone and soft tissue tumors referred to a sarcoma center

被引:0
|
作者
Kawai, Akira [1 ,2 ]
Yoshida, Akihiko [2 ,3 ]
Shimoi, Tatsunori [2 ,4 ]
Kobayashi, Eisuke [1 ,2 ]
Yonemori, Kan [4 ]
Ogura, Koichi [1 ]
Iwata, Shintaro [1 ,2 ]
Toshirou, Nishida [2 ,5 ]
机构
[1] Natl Canc Ctr, Dept Musculoskeletal Oncol & Rehabil Med, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pathol, Tokyo, Japan
[4] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan
[5] Japan Community Hlth Care Org Osaka Hosp, Osaka, Japan
关键词
bone and soft tissue tumors; concordance; histological diagnosis; rare cancers; treatment changes; OPEN-LABEL; PATHOLOGY; OPINIONS;
D O I
10.1111/cas.16211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histological diagnosis of sarcomas (malignant bone and soft tissue tumors) is challenging due to their rarity, morphological diversity, and constantly evolving diagnostic criteria. In this study, we aimed to assess the concordance in histological diagnosis of bone and soft tissue tumors between referring hospitals and a tertiary sarcoma center and analyzed the clinical impact of the diagnostic alteration. We analyzed 628 consecutively accessioned specimens from 624 patients who visited a specialized sarcoma center for treatment. The diagnoses at referring hospitals and those at the sarcoma center were compared and classified into four categories: agreed, disagreed, specified, and de-specified. Of the 628 specimens, the diagnoses agreed in 403 (64.2%) specimens, whereas some changes were made in 225 (35.8%) specimens: disagreed in 153 (24.3%), specified in 52 (8.3%), and de-specified in 20 (3.2%) cases. The benign/intermediate/malignant judgment changed for 92 cases (14.6%). The diagnostic change resulted in patient management modification in 91 cases (14.5%), including surgical and medical treatment changes. The main inferred reason for the diagnostic discrepancies was a different interpretation of morphological findings of the tumor, which accounted for 48.9% of the cases. This was followed by the unavailability of specialized immunohistochemical antibodies and the unavailability of genetic analysis. In summary, our study clarified the actual clinical impact of diagnostic discrepancy in bone and soft tissue tumors. This may underscore the value of pathology consultation, facilitating access to specialized diagnostic tools, and continued education. These measures are expected to improve diagnostic precision and ultimately benefit patients. The diagnoses at referring hospitals and those at the sarcoma center were compared. Of the 628 specimens the diagnoses agreed in 403 (64.2%) specimens, whereas some changes were made in 225 (35.8%) specimens: disagreed in 153 (24.3%), specified in 52 (8.3%), and de-specified in 20 (3.2%) cases. The diagnostic change resulted in patient management modification in 91 cases (14.5%), including surgical and medical treatment changes.image
引用
收藏
页码:2831 / 2838
页数:8
相关论文
共 50 条
  • [1] Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
    Kawai, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1057 - S1057
  • [2] Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center
    Dyrop, Heidi B.
    Vedsted, Peter
    Safwat, Akmal
    Maretty-Nielsen, Katja
    Hansen, Bjarne H.
    Jorgensen, Peter H.
    Baad-Hansen, Thomas
    Keller, Johnny
    ACTA ORTHOPAEDICA, 2014, 85 (06) : 657 - 662
  • [3] Bone and soft tissue tumors: diagnostic principles
    Leithner, Andreas
    Windhager, Reinhard
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (1-2) : 21 - 26
  • [4] Diagnostic Immunohistochemistry for Soft Tissue and Bone Tumors: An Update
    Schaefer, Inga-Marie
    Hornick, Jason L.
    ADVANCES IN ANATOMIC PATHOLOGY, 2018, 25 (06) : 400 - 412
  • [5] DIAGNOSTIC STRATEGY FOR BONE AND SOFT-TISSUE TUMORS
    SIMON, MA
    FINN, HA
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1993, 75A (04): : 622 - 631
  • [6] Diagnostic imaging of bone and soft tissue tumors.
    Bertschinger, K
    Exner, GU
    Hodler, J
    TUMORDIAGNOSTIK & THERAPIE, 1999, 20 (03) : 71 - 78
  • [7] Cryoablation for Malignant Bone and Soft Tissue Tumors and Histological Assessment of Ablated Tumors
    Asanuma, Kunihiro
    Nakatsuka, Atsuhiro
    Nakamura, Tomoki
    Fujimori, Masashi
    Yamanaka, Takashi
    Hagi, Tomohito
    Matsuyama, Yumi
    Iino, Takahiro
    Hasegawa, Masahiro
    ANTICANCER RESEARCH, 2024, 44 (12) : 5463 - 5476
  • [8] Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
    Thongthammachat, K.
    Chantharassamee, J.
    Muangsomboon, S.
    Nimmannit, A.
    Chandhanayingyong, C.
    Akewanlop, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1049 - S1049
  • [9] The clinical efficacy of eribulin to soft tissue sarcoma patients: differences in histological subtypes
    Nakano, Kenji
    Funauchi, Yuki
    Hayakawa, Keiko
    Tanizawa, Taisuke
    Ae, Keisuke
    Matsumoto, Seiichi
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Soft tissue melanoma (clear cell sarcoma) -: Histological, Immunohistochemical and clinical features
    Plötz, S
    Bieder, S
    Krüger, H
    Hein, R
    Ring, J
    Plötz, W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 721 - 721